Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT06043817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06043817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 26, 2023
Completion date
December 1, 2029
Enrollment
345 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

egfr/her2 exon 20 insertion mutation, non-small cell lung cancer, nsclc